The Journal of Contemporary Dental Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  25 (2024)
Volume  24 (2023)
Volume  23 (2022)
Volume  22 (2021)
Volume  21 (2020)
Volume  20 (2019)
Volume  19 (2018)
Volume  18 (2017)
Volume  17 (2016)
Volume  16 (2015)
Volume  15 (2014)
Volume  14 (2013)
Volume  13 (2012)
Volume  12 (2011)
Volume  11 (2010)
Volume  10 (2009)
Volume  9 (2008)
Volume  8 (2007)
Volume  7 (2006)
Volume  6 (2005)
Volume  5 (2004)
Volume  4 (2003)
Volume  3 (2002)
Volume  2 (2001)
Volume  1 (1999)
Related articles

VOLUME 16 , ISSUE 7 ( July, 2015 ) > List of Articles

REVIEW ARTICLE

Inflammation and Oral Cancer: An Update Review on Targeted Therapies

Shankar Gouda Patil, Anuprita Patil, Rahul Anand

Citation Information : Patil SG, Patil A, Anand R. Inflammation and Oral Cancer: An Update Review on Targeted Therapies. J Contemp Dent Pract 2015; 16 (7):595-602.

DOI: 10.5005/jp-journals-10024-1727

Published Online: 01-01-2016

Copyright Statement:  Copyright © 2015; The Author(s).


Abstract

How to cite this article

Sarode GS, Sarode SC, Patil A, Anand R, Patil SG, Rao RS, Augustine D. Inflammation and Oral Cancer: An Update Review on Targeted Therapies. J Contemp Dent Pract 2015;16(7):595-602.

PDF Share
  1. Head and neck cancer. N Engl J Med 1993;328(3):184-194.
  2. Recent advances in epidemiology of head and neck cancer. Curr Opin Oncol 1992;4(3):471-477.
  3. Oral cancers in India. Semin Oncol 2001;28(2):169-173.
  4. Early detection of oral cancer: detector lies within. Oral Oncol 2012;48(3):193-194.
  5. OP(Oral Pathologist)inion matters. Oral Oncol 2012;48(11):e47-48.
  6. Criteria to define true second primary oral squamous cell carcinoma. Oral Oncol 2010;46(11):834.
  7. STAT signaling in head and neck cancer. Oncogene 2000;19(15):2489-2495.
  8. Multiple primary malignant tumors in patients with head and neck cancer: results of a prospective study and future perspectives. Laryngoscope 1998;108(2):250-256.
  9. The molecular biology of oral carcinogenesis: toward a tumor progression model. J Oral Maxillofac Surg 1997;55(6):613-623.
  10. Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 2000;53(4):165-172.
  11. Cell death regulation in oral squamous cell carcinoma: methodological considerations and clinical significance. J Oral Pathol Med 2003;32(3):125-138.
  12. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30(7):1073-1081.
  13. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7(3):211-217.
  14. Inflammation in the context of oral cancer. Oral Oncol 2013;49(9):887-892.
  15. A new classification for potentially malignant disorders of the oral cavity. Oral Oncol 2011;47(9):920-921.
  16. Oral potentially malignant disorders: precising the definition. Oral Oncol 2012;48(9):759-760.
  17. Oral (mucosal) potentially malignant disorders. Oral Oncol 2012;48(10):e35-36.
  18. Distinct role of intrarenal cyclooxygenase-1/2 in chronic unilateral renal ischemia. Nephron 2002;92(1):183-191.
  19. Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma. Histopathology 2010;57(1):90-100.
  20. The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. J Exp Clin Cancer Res 2011;30:13.
  21. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57(7):1276-1280.
  22. Immunity, inflammation, and cancer. Cell 2010;140(6):883-899.
  23. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29(6):781-788.
  24. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10(17):5930-5939.
  25. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 2001;92(7):1888-1895.
  26. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila) 2008;1(5):339-348.
  27. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14(7):2095-2101.
  28. Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 1996;106(2):129-134.
  29. Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 2008;23(10):1269-1278.
  30. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositidedependent protein kinase-1 inhibitors. Cancer Res 2004;64(12):4309-4318.
  31. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 2005;7(5):R 796-807.
  32. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005;11(17):6261-6269.
  33. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005;4(9):1448-1455.
  34. Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase 1b and Pharmacokinetic Study. Cancer Prev Res (Phila) 2014 Mar;7(3):283-291.
  35. CTGF inhibits cell motility and COX-2 expression in oral cancer cells. Int Immunopharmacol 2011;11(8):948-954.
  36. CCN proteins: multifunctional signalling regulators. Lancet 2004;363(9402):62-64.
  37. MAP kinases: charting the regulatory pathways. Science 1992;257(5075):1355-1356.
  38. Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint. EMBO J 2006;25(4):763-773.
  39. Quantification of p38alphaMAP kinase: a prognostic marker in HNSCC with respect to radiation therapy. Clin Chim Acta 2012;413(1):219-225.
  40. Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38α MAP kinase. Biochim Biophys Acta 2013;1830(3):2763-2769.
  41. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8(4):945-954.
  42. The STATs of cancer.new molecular targets come of age. Nat Rev Cancer 2004;4(2):97-105.
  43. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 2013;4(3):176-185.
  44. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling. Oral Oncol 2014 Oct;50(10):930-941.
  45. Guggulsterone inhibits NF-kappa B and Ikappa Balpha kinase activation, suppresses expression of antiapoptotic gene products, and enhances apoptosis. J Biol Chem 2004;279(45):47148-47158.
  46. Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak. Mol Cancer Ther 2005;4(11):1747-1754.
  47. Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Mol Cancer Ther 2005;4(12):1982-1992.
  48. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem Pharmacol 2007;74(1):118-130.
  49. Guggulsteroneinduced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase. Cancer Res 2007;67(15):7439-7449.
  50. Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts. Cancer Lett 2009;279(1):93-100.
  51. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res 2008;68(11):4406-4415.
  52. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009;30(11):1848-1856.
  53. Guggulsterone (GS) inhibits smokeless tobacco and nicotineinduced NF-κB and STAT3 pathways in head and neck cancer cells. Carcinogenesis 2011;32(3):368-380.
  54. Guggulsterone targets smokeless tobacco induced PI3K/Akt pathway in head and neck cancer cells. PLoS One 2011;6(2):e14728.
  55. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 2002;4(6):408-415.
  56. RhoC GT Pase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000;60(20):5832-5838.
  57. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 2004;6(1):R110-115.
  58. Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130(3):295-302.
  59. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000;2(5):418-425.
  60. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2006;12(15):4485-4490.
  61. Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol 2013;49(8):778-786.
  62. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003;2(10):941-948.
  63. Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARgamma. Biochim Biophys Acta 2012;1822(7):1090-1095.
  64. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010;10:365-376.
  65. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012;12(3):181-195.
  66. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 2008;73(3):709-717.
  67. Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide. Cancer Sci 2003;94(4):365-371.
  68. Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2007;25(18 Suppl):1511.
  69. Pioglitazone and risk of bladder cancer among diabetic patients in France: a opulation based cohort study. Diabetologia 2012;55(7):1953-1962.
  70. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents—implications for drug interactions. Br J Clin Pharmacol 1995;40(6):523-530.
  71. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acutephase response. Br J Cancer 2002;87(3):277-280.
  72. Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4(4):224-232.
  73. Interleukin 1β inhibits CAR induced expression of hepatic genes involved in drug and bilurubin clearance. Hepatology 2004;40(4):951-960.
  74. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology 2002;181-182:207-210.
  75. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000;274(3):707-713.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.